CanSino Biologics, Inc. (06185.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 26.98

From 52W high−51.90%

Volume5.59M

Market capHKD 6.51B

P/E (TTM)140.2x

P/S (TTM)4.5x

Div yield—

Key dataSep 18, 2026

Open

HKD 26.98

From 52W high

−51.90%

Volume

5.59M

Market cap

HKD 6.51B

ValuationView details →

P/E (Fwd)

41.3x

EV/EBITDA

123.3x

P/E (TTM)

140.2x

RSI (14)

47.1

MomentumView details →

1D Return

+1.62%

YTD Return

−24.51%

ValuationView details →

P/E (Fwd)

41.3x

P/E (TTM)

140.2x

EV/EBITDA

123.3x

EV/Sales

3.8x

P/S (TTM)

4.5x

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

71.69%

Net Margin

3.31%

EBITDA Margin

3.11%

ROE (TTM)

0.82%

ROA (TTM)

0.59%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

+32.56%

EPS YoY

+123.85%

FCF YoY

+52.59%

Revenue CAGR 3Y

+0.03%

EPS CAGR 3Y

+107.19%

EBITDA YoY

+257.69%

MomentumView details →

1D Return

+1.62%

YTD Return

−24.51%

1Y Return

−48.91%

RSI (14)

47.1

vs 50D SMA

+0.95%

vs 200D SMA

−13.62%

Capital & dividendView details →

Debt/Equity

0.20x

Current Ratio

4.39x

Quick Ratio

3.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.19

EPS Surprise

−21.75%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.30

Avg Surprise (4Q)

−21.75%

Rev Surprise

14.02%

Financials snapshotView financials →

Revenue (TTM)

1.23B

Net Income (TTM)

40.63M

Op. CF (TTM)

40.25M

Next earningsNov 2, 2026 →

Latest newsMore news →

CanSino Biologics reported its first-half 2026 results, with revenue of 550 million yuan, up 43.81% year-on-year, and a net loss attributable to shareholders of 720,800 yuan, compared with a loss of 13.4854 million yuan in the same period of 2025.24d ago

CanSino Biologics announced it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as InVivoCAR-related therapies, all currently in early stages.25d ago

Similar companies

Lantheus Holdings, Inc.LNTH 亚虹医药-U688176.SH 百克生物688276.SH 昆药集团600422.SH 康缘药业600557.SH Sihuan Pharmaceutical Holdings Group Ltd.00460.HK Find similar companies →

Latest newsMore news →

CanSino Biologics reported its first-half 2026 results, with revenue of 550 million yuan, up 43.81% year-on-year, and a net loss attributable to shareholders of 720,800 yuan, compared with a loss of 13.4854 million yuan in the same period of 2025.24d ago CanSino Biologics announced it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as InVivoCAR-related therapies, all currently in early stages.25d ago